Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381)


  • Product name
    Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)]
    See all Alpha-synuclein primary antibodies
  • Description
    Rabbit monoclonal [MJF-R13 (8-8)] to Alpha-synuclein (phospho S129)
  • Host species
  • Specificity
    ab168381 only detects alpha Synuclein phosphorylated on Ser129.
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human Alpha-synuclein (phospho S129). The exact sequence is proprietary.
    Database link: P37840

  • Positive control
    • Recombinant alpha-synuclein, expressed in BL21 bacterial cells in the presence of Human Polo-Like Kinase 2; HEK whole cell lysates, stably-transfected with Polo-Like Kinase 2 and alpha Synuclein.
  • General notes

    Alpha-synuclein was the first gene to be linked to Parkinson’s disease (PD) and remains the most promising link to PD pathogenesis, where there is genetic evidence that it may play a causal role. In the brain, alpha-synuclein is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.
    Recent studies also indicate that alpha-synuclein undergoes post-translational modification. Though the role of many of these modifications is still under investigation, phosphorylation at Serine 129 may affect alpha-synuclein aggregations and may also serve as marker of disease pathogenesis. With the advent of this phospho-specific Serine 129 antibody, The Michael J. Fox Foundation hopes to ensure that the putative role of this modification can be further examined by all researchers.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab168381 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Predicted molecular weight: 14 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
  • Target

    • Function
      May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
    • Tissue specificity
      Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
    • Involvement in disease
      Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
      Parkinson disease 1
      Parkinson disease 4
      Dementia Lewy body
    • Sequence similarities
      Belongs to the synuclein family.
    • Domain
      The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
    • Post-translational
      Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
      Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
      Ubiquitinated. The predominant conjugate is the diubiquitinated form.
      Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure.
    • Cellular localization
      Cytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons.
    • Information by UniProt
    • Database links
    • Alternative names
      • Alpha synuclein antibody
      • Alpha-synuclein antibody
      • Alpha-synuclein, isoform NACP140 antibody
      • alphaSYN antibody
      • MGC105443 antibody
      • MGC110988 antibody
      • MGC127560 antibody
      • MGC64356 antibody
      • NACP antibody
      • Non A beta component of AD amyloid antibody
      • Non A4 component of amyloid antibody
      • Non A4 component of amyloid precursor antibody
      • Non-A beta component of AD amyloid antibody
      • Non-A-beta component of alzheimers disease amyloid , precursor of antibody
      • Non-A4 component of amyloid precursor antibody
      • Non-A4 component of amyloid, precursor of antibody
      • OTTHUMP00000218549 antibody
      • OTTHUMP00000218551 antibody
      • OTTHUMP00000218552 antibody
      • OTTHUMP00000218553 antibody
      • OTTHUMP00000218554 antibody
      • PARK 1 antibody
      • PARK 4 antibody
      • PARK1 antibody
      • PARK4 antibody
      • Parkinson disease (autosomal dominant, Lewy body) 4 antibody
      • Parkinson disease familial 1 antibody
      • SNCA antibody
      • Snca synuclein, alpha (non A4 component of amyloid precursor) antibody
      • SYN antibody
      • Synuclein alpha antibody
      • Synuclein alpha 140 antibody
      • Synuclein, alpha (non A4 component of amyloid precursor) antibody
      • SYUA_HUMAN antibody
      see all


    • All lanes : Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) at 1/1000 dilution

      Lane 1 : Recombinant alpha Synuclein expressed in BL21 bacterial cells
      Lane 2 : Recombinant alpha Synuclein expressed in BL21 bacterial cells, in the presence of Human Polo-Like Kinase 2
      Lane 3 : HEK whole cell lysates, stably-transfected with Polo-Like Kinase 2 and alpha Synuclein

      Predicted band size: 14 kDa


    This product has been referenced in:
    • Tolö J  et al. Pathophysiological Consequences of Neuronal a-Synuclein Overexpression: Impacts on Ion Homeostasis, Stress Signaling, Mitochondrial Integrity, and Electrical Activity. Front Mol Neurosci 11:49 (2018). Read more (PubMed: 29563864) »
    • Henderson MX  et al. LRRK2 activity does not dramatically alter a-synuclein pathology in primary neurons. Acta Neuropathol Commun 6:45 (2018). Read more (PubMed: 29855356) »

    See all 6 Publications for this product

    Customer reviews and Q&As

    Immunohistochemistry (PFA perfusion fixed frozen sections)
    Mouse Tissue sections (Brain)
    Antigen retrieval step
    Blocking step
    Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C

    María Izco

    Verified customer

    Submitted Feb 22 2018

    Western blot
    Mouse Cell lysate - whole cell (Cortical neuron)
    Gel Running Conditions
    Reduced Denaturing
    Loading amount
    30 µg
    Cortical neuron
    Blocking step
    Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C

    Mr. Chun Chau SUNG

    Verified customer

    Submitted Dec 06 2017

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Mouse Tissue sections (Intestine)
    Antigen retrieval step
    Heat mediated - Buffer/Enzyme Used: citrate
    Yes - triton X100
    Blocking step
    Serum as blocking agent for 30 minute(s) · Concentration: 4% · Temperature: 25°C

    Abcam user community

    Verified customer

    Submitted Jul 18 2016


    Sign up